Lead program NeoVAC

Immunetune’s lead program NeoVAC is a personalized neoantigen DNA vaccine harboring more than 20 neoantigens to elicit a powerful tumor-specific immune response. It has obtained preclinical Proof of Concept in cancer models including the combination with checkpoint inhibitors, which has been published in the journal Oncoimmunology in 2019.

The company has received scientific advice from the Paul-Ehrlich-Institute in Germany for the development plan into the clinic, and is now finalizing formal preclinical studies to enable initiation of first-in-man Phase I/II clinical studies in 2022.